111In-pentetreotide detection of gastrinoma before and after surgery

Francesco Scopinaro, Orazio Schillaci, Gianfranco Delle Fave, Roberta Danieli, Alberto Materia, Rosanna Tavolaro, Stefano Angeletti, Massimo Marignani, Rita Massa, Gianfranco Gualdi, Elisabetta Polettini, Valentina Picardi, Nicola Basso

Research output: Contribution to journalArticle

Abstract

Eighteen patients with Zollinger-Ellison syndrome were studied with 111In-pentetreotide SPECT in order to localize gastrinoma, the tumour responsible for this pathology. NMR imaging was also carried out. Eighteen patients were operated. 111In-pentetreotide was reinjected 4 hours before operation and the radioactivity of the excised tumours counted. The nature of the withdrawn tissues was assessed by immunohistochemistry (chromogranina A). The scintigraphy was repeated 3-6 months after surgery. 111In pentetreotide SPECT was more sensitive than NMR. It was also absolutely specific because all the radioactive tumours excised showed positive chromogranin A staining. The radioactivity/gram counted in gastrinomas exceeded 10 fold the hepatic and biliary radioactivity and 20-100 folds the radioactivity of blood and omentum. In all the operated patients but three, the scintigraphy performed after surgery did not detect tumours. However complete eradication did not occur, because though 3-6 months after surgery the gastrinemia was significantly lower with respect to pre-surgery results it did not return to normal values in all patients but two.

Original languageEnglish
Pages (from-to)1757-1760
Number of pages4
JournalAnticancer Research
Volume17
Issue number3 B
Publication statusPublished - 1997

Fingerprint

Gastrinoma
Radioactivity
Single-Photon Emission-Computed Tomography
Radionuclide Imaging
Neoplasms
Zollinger-Ellison Syndrome
Chromogranin A
Omentum
Reference Values
Immunohistochemistry
Magnetic Resonance Imaging
Pathology
Staining and Labeling
pentetreotide
Liver

Keywords

  • In-pentetreotide
  • Gastrinoma
  • Scintigraphy
  • Somatostatin receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Scopinaro, F., Schillaci, O., Fave, G. D., Danieli, R., Materia, A., Tavolaro, R., ... Basso, N. (1997). 111In-pentetreotide detection of gastrinoma before and after surgery. Anticancer Research, 17(3 B), 1757-1760.

111In-pentetreotide detection of gastrinoma before and after surgery. / Scopinaro, Francesco; Schillaci, Orazio; Fave, Gianfranco Delle; Danieli, Roberta; Materia, Alberto; Tavolaro, Rosanna; Angeletti, Stefano; Marignani, Massimo; Massa, Rita; Gualdi, Gianfranco; Polettini, Elisabetta; Picardi, Valentina; Basso, Nicola.

In: Anticancer Research, Vol. 17, No. 3 B, 1997, p. 1757-1760.

Research output: Contribution to journalArticle

Scopinaro, F, Schillaci, O, Fave, GD, Danieli, R, Materia, A, Tavolaro, R, Angeletti, S, Marignani, M, Massa, R, Gualdi, G, Polettini, E, Picardi, V & Basso, N 1997, ' 111In-pentetreotide detection of gastrinoma before and after surgery', Anticancer Research, vol. 17, no. 3 B, pp. 1757-1760.
Scopinaro F, Schillaci O, Fave GD, Danieli R, Materia A, Tavolaro R et al. 111In-pentetreotide detection of gastrinoma before and after surgery. Anticancer Research. 1997;17(3 B):1757-1760.
Scopinaro, Francesco ; Schillaci, Orazio ; Fave, Gianfranco Delle ; Danieli, Roberta ; Materia, Alberto ; Tavolaro, Rosanna ; Angeletti, Stefano ; Marignani, Massimo ; Massa, Rita ; Gualdi, Gianfranco ; Polettini, Elisabetta ; Picardi, Valentina ; Basso, Nicola. / 111In-pentetreotide detection of gastrinoma before and after surgery. In: Anticancer Research. 1997 ; Vol. 17, No. 3 B. pp. 1757-1760.
@article{f71bb1baed614c349b23d98765794553,
title = "111In-pentetreotide detection of gastrinoma before and after surgery",
abstract = "Eighteen patients with Zollinger-Ellison syndrome were studied with 111In-pentetreotide SPECT in order to localize gastrinoma, the tumour responsible for this pathology. NMR imaging was also carried out. Eighteen patients were operated. 111In-pentetreotide was reinjected 4 hours before operation and the radioactivity of the excised tumours counted. The nature of the withdrawn tissues was assessed by immunohistochemistry (chromogranina A). The scintigraphy was repeated 3-6 months after surgery. 111In pentetreotide SPECT was more sensitive than NMR. It was also absolutely specific because all the radioactive tumours excised showed positive chromogranin A staining. The radioactivity/gram counted in gastrinomas exceeded 10 fold the hepatic and biliary radioactivity and 20-100 folds the radioactivity of blood and omentum. In all the operated patients but three, the scintigraphy performed after surgery did not detect tumours. However complete eradication did not occur, because though 3-6 months after surgery the gastrinemia was significantly lower with respect to pre-surgery results it did not return to normal values in all patients but two.",
keywords = "In-pentetreotide, Gastrinoma, Scintigraphy, Somatostatin receptor",
author = "Francesco Scopinaro and Orazio Schillaci and Fave, {Gianfranco Delle} and Roberta Danieli and Alberto Materia and Rosanna Tavolaro and Stefano Angeletti and Massimo Marignani and Rita Massa and Gianfranco Gualdi and Elisabetta Polettini and Valentina Picardi and Nicola Basso",
year = "1997",
language = "English",
volume = "17",
pages = "1757--1760",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 B",

}

TY - JOUR

T1 - 111In-pentetreotide detection of gastrinoma before and after surgery

AU - Scopinaro, Francesco

AU - Schillaci, Orazio

AU - Fave, Gianfranco Delle

AU - Danieli, Roberta

AU - Materia, Alberto

AU - Tavolaro, Rosanna

AU - Angeletti, Stefano

AU - Marignani, Massimo

AU - Massa, Rita

AU - Gualdi, Gianfranco

AU - Polettini, Elisabetta

AU - Picardi, Valentina

AU - Basso, Nicola

PY - 1997

Y1 - 1997

N2 - Eighteen patients with Zollinger-Ellison syndrome were studied with 111In-pentetreotide SPECT in order to localize gastrinoma, the tumour responsible for this pathology. NMR imaging was also carried out. Eighteen patients were operated. 111In-pentetreotide was reinjected 4 hours before operation and the radioactivity of the excised tumours counted. The nature of the withdrawn tissues was assessed by immunohistochemistry (chromogranina A). The scintigraphy was repeated 3-6 months after surgery. 111In pentetreotide SPECT was more sensitive than NMR. It was also absolutely specific because all the radioactive tumours excised showed positive chromogranin A staining. The radioactivity/gram counted in gastrinomas exceeded 10 fold the hepatic and biliary radioactivity and 20-100 folds the radioactivity of blood and omentum. In all the operated patients but three, the scintigraphy performed after surgery did not detect tumours. However complete eradication did not occur, because though 3-6 months after surgery the gastrinemia was significantly lower with respect to pre-surgery results it did not return to normal values in all patients but two.

AB - Eighteen patients with Zollinger-Ellison syndrome were studied with 111In-pentetreotide SPECT in order to localize gastrinoma, the tumour responsible for this pathology. NMR imaging was also carried out. Eighteen patients were operated. 111In-pentetreotide was reinjected 4 hours before operation and the radioactivity of the excised tumours counted. The nature of the withdrawn tissues was assessed by immunohistochemistry (chromogranina A). The scintigraphy was repeated 3-6 months after surgery. 111In pentetreotide SPECT was more sensitive than NMR. It was also absolutely specific because all the radioactive tumours excised showed positive chromogranin A staining. The radioactivity/gram counted in gastrinomas exceeded 10 fold the hepatic and biliary radioactivity and 20-100 folds the radioactivity of blood and omentum. In all the operated patients but three, the scintigraphy performed after surgery did not detect tumours. However complete eradication did not occur, because though 3-6 months after surgery the gastrinemia was significantly lower with respect to pre-surgery results it did not return to normal values in all patients but two.

KW - In-pentetreotide

KW - Gastrinoma

KW - Scintigraphy

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=0030610279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030610279&partnerID=8YFLogxK

M3 - Article

C2 - 9179230

AN - SCOPUS:0030610279

VL - 17

SP - 1757

EP - 1760

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 B

ER -